Patents by Inventor David Michael Remick

David Michael Remick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Processes for the preparation of selective estrogen receptor degraders
    Patent number: 11926634
    Abstract: Disclosed are methods of making selective estrogen receptor degraders (SERDs) of Formula A, as well as intermediates thereof, salts thereof including a pharmaceutically acceptable salt, and pharmaceutical compositions thereof: wherein either R1 or R2 is independently Cl, F, —CF3, or —CH3, and the other is H; and R7 is H or PG.
    Type: Grant
    Filed: January 27, 2023
    Date of Patent: March 12, 2024
    Assignee: Eli Lilly and Company
    Inventors: Alonso Jose Arguelles Delgado, Boris Arnoldovich Czeskis, Mai Khanh Nguyen Hawk, Douglas Patton Kjell, Yu Lu, Nicholas Andrew Magnus, David Michael Remick
  • SSTR4 AGONIST SALTS
    Publication number: 20240067628
    Abstract: The present invention relates to specific salts of (1S,5R)-(1?,5?,6?)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.
    Type: Application
    Filed: August 7, 2023
    Publication date: February 29, 2024
    Inventors: David Andrew COATES, David Michael REMICK
  • SSTR4 agonist salts
    Patent number: 11834435
    Abstract: The present invention relates to specific salts of (1S,5R)-(1?,5?,6?)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.
    Type: Grant
    Filed: September 14, 2022
    Date of Patent: December 5, 2023
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, David Michael Remick
  • Polymorphs of an SSAO inhibitor
    Patent number: 11820754
    Abstract: Provided herein are polymorphs of (2E)-3-fluoro-2-({[2-(4-methoxypiperidin-1-yl)pyrimidin-5-yl]oxy}methyl)prop-2-en-1-aminium 4-methylbenzenesulfonate, compositions thereof, methods of preparation thereof, and methods of use thereof.
    Type: Grant
    Filed: August 24, 2021
    Date of Patent: November 21, 2023
    Assignee: Eli Lilly and Company
    Inventor: David Michael Remick
  • PROCESSES FOR THE PREPARATION OF SELECTIVE ESTROGEN RECEPTOR DEGRADERS
    Publication number: 20230242545
    Abstract: Disclosed are methods of making selective estrogen receptor degraders (SERDs) of Formula A, as well as intermediates thereof, salts thereof including a pharmaceutically acceptable salt, and pharmaceutical compositions thereof: wherein either R1 or R2 is independently Cl, F, —CF3, or —CH3, and the other is H; and R7 is H or PG.
    Type: Application
    Filed: January 27, 2023
    Publication date: August 3, 2023
    Inventors: Alonso Jose ARGUELLES DELGADO, Boris Arnoldovich CZESKIS, Mai Khanh Nguyen HAWK, Douglas Patton KJELL, Yu LU, Nicholas Andrew MAGNUS, David Michael REMICK
  • SSTR4 AGONIST SALTS
    Publication number: 20230099116
    Abstract: The present invention relates to specific salts of (1S,5R)-(1?,5?,6?)-N-[1,1-dimethyl-2-[(3-methyl-2-pyridyl)oxy]ethyl]-3-azabicyclo[3.1.0]hexane-6-carboxamide, to pharmaceutical compositions comprising said salts, to methods of using said salts to treat physiological disorders, and to intermediates useful in the synthesis of the salts.
    Type: Application
    Filed: September 14, 2022
    Publication date: March 30, 2023
    Inventors: David Andrew COATES, David Michael REMICK
  • CRYSTALLINE FORMS OF A CD73 INHIBITOR
    Publication number: 20220289716
    Abstract: The present invention relates to crystalline forms of 5-[5-[2-isopropylcyclopropyl]-6-methyl-pyridazin-3-yl]-1H-pyrimidine-2,4-dione, and pharmaceutical compositions comprising them, which inhibit the activity of CD73 and are useful for treating cancer.
    Type: Application
    Filed: August 24, 2020
    Publication date: September 15, 2022
    Inventors: Susana Maria GARCIA-CERRADA, Yu LU, David Michael REMICK
  • SALTS OF 5,6-DIHYDRO-4H-THIENO[2,3-C]PYRROL-4-ONE COMPOUND AS ERK INHIBITORS
    Publication number: 20220153750
    Abstract: The present invention provides novel crystalline salt forms of 6,6-dimethyl-2-{2-[(1-methyl-1H-pyrazol-5-yl)amino]pyrimidin-4-yl}-5-[2-(morpholin-4-yl)ethyl]-5,6-dihydro-4H-thieno[2,3-c]pyrrol-4-one.
    Type: Application
    Filed: March 19, 2020
    Publication date: May 19, 2022
    Inventors: David Andrew COATES, Sajan JOSEPH, Mark Andrew POLIZZI, David Michael REMICK
  • POLYMORPHS OF AN SSAO INHIBITOR
    Publication number: 20220089563
    Abstract: Provided herein are polymorphs of (2E)-3-fluoro-2-({[2-(4-methoxypiperidin-1-yl)pyrimidin-5-yl]oxy}methyl)prop-2-en-1-aminium 4-methylbenzenesulfonate, compositions thereof, methods of preparation thereof, and methods of use thereof.
    Type: Application
    Filed: August 24, 2021
    Publication date: March 24, 2022
    Inventor: David Michael REMICK
  • Novel Treprostinil Salt
    Publication number: 20220047535
    Abstract: A novel salt of treprostinil and methods of its preparation and use are disclosed.
    Type: Application
    Filed: September 11, 2019
    Publication date: February 17, 2022
    Inventor: David Michael Remick
  • (E)-1-(4-(DIMETHYLAMINO)BUT-2-ENOYL)PYRROLIDIN-3-YL 4-((3-ISOPROPYL-5-METHYLPYRAZOLO[1,5-A]PYRIMIDIN-7-YL)AMINO)PIPERIDINE-1-CARBOXYLATE FOR INHIBITING CDK7
    Publication number: 20210032257
    Abstract: The present invention provides novel CDK7 inhibitors and pharmaceutical compositions thereof: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 22, 2020
    Publication date: February 4, 2021
    Inventors: David Andrew COATES, Carlos MONTERO, Bharvin Kumar Rameschandra PATEL, David Michael REMICK, Vipin YADAV
  • (E)-1-(4-(dimethylamino)but-2-enoyl)pyrrolidin-3-yl 4-((3-isopropyl-5-methylpyrazolo[1,5-a]pyrimidin-7-yl)amino)piperidine-1-carboxylate for inhibiting CDK7
    Patent number: 10787460
    Abstract: The present invention provides novel CDK7 inhibitors and pharmaceutical compositions thereof: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: September 26, 2019
    Date of Patent: September 29, 2020
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Carlos Montero, Bharvin Kumar Rameschandra Patel, David Michael Remick, Yipin Yadav
  • (E)-1-(4-(DIMETHYLAMINO)BUT-2-ENOYL)PYRROLIDIN-3-YL 4-((3-ISOPROPYL-5-METHYLPYRAZOLO[1,5-A]PYRIMIDIN-7-YL)AMINO)PIPERIDINE-1-CARBOXYLATE FOR INHIBITING CDK7
    Publication number: 20200017513
    Abstract: The present invention provides novel CDK7 inhibitors and pharmaceutical compositions thereof: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: September 26, 2019
    Publication date: January 16, 2020
    Inventors: David Andrew COATES, Carlos MONTERO, Bharvin Kumar Rameschandra PATEL, David Michael REMICK, Yipin YADAV
  • COMPOUNDS USEFUL FOR INHIBITING CDK7
    Publication number: 20190144456
    Abstract: The present invention provides novel CDK7 inhibitors and pharmaceutical compositions thereof: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: November 9, 2018
    Publication date: May 16, 2019
    Inventors: David Andrew Coates, Carlos Montero, Bharvin Kumar Rameschandra Patel, David Michael Remick, Vipin Yadav
  • Selective BACE1 inhibitors
    Patent number: 10011610
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: April 22, 2016
    Date of Patent: July 3, 2018
    Assignee: Eli Lilly and Company
    Inventors: David Michael Remick, Simon James Richards, Adam Jan Sanderson
  • Selective BACE1 Inhibitors
    Publication number: 20160318953
    Abstract: The present invention provides a compound of Formula I: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: April 22, 2016
    Publication date: November 3, 2016
    Inventors: David Michael Remick, Simon James Richards, Adam Jan Sanderson
  • -4-[[(5)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
    Patent number: 8299060
    Abstract: Abstract Compounds of a formula entitled, trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid, as a free acid or a pharmaceutically acceptable salt thereof, hydrate, and hydrate in crystalline form; pharmaceutical formulations; and methods of use are disclosed.
    Type: Grant
    Filed: June 28, 2010
    Date of Patent: October 30, 2012
    Assignee: Eli Lilly and Company
    Inventors: Xinchao Chen, Scott Alan Frank, Steven Wayne Pedersen, David Michael Remick
  • Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
    Publication number: 20120058990
    Abstract: Abstract Compounds of a formula entitled, trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid, as a free acid or a pharmaceutically acceptable salt thereof, hydrate, and hydrate in crystalline form; pharmaceutical formulations; and methods of use are disclosed.
    Type: Application
    Filed: June 28, 2010
    Publication date: March 8, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Xinchao Chen, Scott Alan Frank, Steven Wayne Pedersen, David Michael Remick
  • Trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
    Publication number: 20100331309
    Abstract: Compounds of a formula entitled, trans-4-[[(5S)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl](2-methyl-2H-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1H-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid, as a free acid or a pharmaceutically acceptable salt thereof; and hydrates and other solvates in crystalline form; pharmaceutical formulations; and methods of use are disclosed.
    Type: Application
    Filed: June 28, 2010
    Publication date: December 30, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Xinchao Chen, Scott Alan Frank, David Michael Remick, Steven Wayne Pedersen
  • Amide prodrug of gemcitabine, compositions and use thereof
    Patent number: 7691827
    Abstract: The present invention relates to the gemcitabine prodrug 1-(2,2-difluoro-2-deoxy-?-D -ribofuranosyl)-4-(2-propyl-1-oxopentyl)aminopyrimidin-2-one useful as an oral drug for the treatment of cancer.
    Type: Grant
    Filed: November 30, 2005
    Date of Patent: April 6, 2010
    Assignee: Eli Lilly and Company
    Inventors: David Michael Bender, David Michael Remick